|
⚠️ Professional Use Only This content is intended exclusively for licensed medical professionals. It does not constitute clinical advice. Always follow applicable regulations and guidelines in your jurisdiction. |
|
✍️ Written by: Celmade Editorial Team | AI-Assisted Content 🔬 Medically Reviewed by: Stella Williams, Medical Aesthetic Injector 📅 Published: May 3rd, 2026 | Last Reviewed: May 3rd, 2026 🔗 View Reviewer Full Profile → celmade.co/pages/team-stella-williams |
|
📌 Editorial Note: This article was drafted with AI assistance and reviewed, fact-checked, and approved by Stella Williams, a qualified Medical Aesthetic Injector. All clinical claims are supported by cited references. |
The submental zone is the best-evidenced and most widely discussed lipolytic application — but it is far from the only one. In international aesthetic practice, particularly in the Korean market where lipolytic treatments have been administered at high volume for over two decades, injectable lipolytics are used routinely across multiple body zones to address localised fat deposits that patients find resistant to diet and exercise and that significantly affect their confidence and comfort.
Off-label applications share the same fundamental biology as submental treatment — deoxycholic acid (DCA) or phosphatidylcholine/DCA (PC/DCA) injected into subcutaneous fat causing permanent adipocyte lysis — but each zone has its own specific anatomical considerations, safety boundaries, injection parameters, and post-treatment expectations. Understanding these zone-specific differences is what separates safe and effective off-label lipolytic practice from the indiscriminate application of a submental protocol to body zones it was not designed for.
This guide covers the most commonly treated body zones in off-label lipolytic practice: the bra-strap and axillary area, the abdomen, the inner thighs, the medial knee, the arms, and the buffalo hump / cervicodosal fat pad. For the complete lipolytic mechanism and safety overview, see the Complete Lipolytic Injectables Guide. For the submental protocol in detail, see our Submental Fat Reduction guide. Browse Celmade's lipolytic product range for CE-marked Korean DCA and PC/DCA formulations.
The Off-Label Framework: Clinical Responsibility and Safety Principles
Before covering individual zones, practitioners must understand the clinical and legal framework for off-label lipolytic use:
|
Off-label use is not the same as unsafe use: Off-label use of a CE-marked medical device or pharmaceutical means using a product outside its specifically approved indications — it does not mean the product is unsafe or the treatment is unproven. The majority of established aesthetic treatments involve some degree of off-label use. The practitioner's responsibility in off-label use is: (1) to have adequate evidence that the treatment produces the claimed effect, (2) to understand the specific anatomy and risks of the proposed zone, (3) to obtain specific informed consent that explicitly includes the off-label nature of the treatment, and (4) to document everything thoroughly. These are the standards the UK regulatory and legal framework expects. |
The following principles apply to all off-label lipolytic zones — in addition to the zone-specific parameters covered below:
• Informed consent must specifically reference off-label use: The consent form for body lipolytic treatment should state that the product is being used outside its specifically approved indications and that the patient understands this.
• The post-treatment inflammatory response will occur in every zone: The adipocyte lysis response — swelling, erythema, induration — is inherent to the mechanism. Body zones typically produce more visible swelling than the submental zone due to gravity and the larger tissue volumes involved. Counsel every body patient as thoroughly as submental patients.
• The same patient selection principles apply: Localised, diet-resistant fat deposit. At or near healthy weight. Stable weight. No significant skin laxity overlying the deposit. No active infection. No contraindications.
• Session spacing is the same: Minimum 6–8 weeks between sessions. Do not re-treat until all swelling from the previous session has fully resolved and the result is assessable.
• Photograph every zone at every session: Standardised photography in consistent positions. The before/after comparison is your most important patient satisfaction tool and your clinical protection.
Zone 1: Bra-Strap Fat and Axillary Fold
|
BRA-STRAP FAT / AXILLARY FOLD — Clinical Overview |
|
Description: Localised fat deposits along the bra-strap line (lateral back fat) and/or the axillary fold (the soft tissue fold visible in the armpit, particularly when the arms are at the sides or when wearing a bra). Why patients care: Bulging fat at the bra line is extremely common and often considered untreatable except through surgery. Even lean patients can have this deposit, which is highly diet-resistant. It is one of the most emotionally significant localised fat concerns — visible in fitted clothing, particularly with sleeve-free tops. Evidence level: Moderate — extensive Korean clinical experience and international practice case series. Less formal RCT evidence than submental but well-established in international practice. Skin laxity consideration: Lower than submental — the skin over the bra-fat zone is generally thicker and more elastic than submental. Skin laxity is less commonly a confounding factor in this zone. Swelling profile: Significant but gravity-dependent. The treated area will be swollen, firm, and tender for 2–4 weeks. Advise patients to wear a supportive bra or compression garment during this period. |
|
Parameter |
Bra-Strap Fat Protocol |
|
Patient position |
Prone or seated — allows access to the lateral back and axillary fold |
|
Needle gauge |
30G or 31G, 13mm |
|
Injection angle |
90 degrees perpendicular — into the subcutaneous fat |
|
Volume per point |
0.2ml per point (DCA product) — same as submental |
|
Point spacing |
1cm grid across the defined fat deposit |
|
Safe zone boundaries |
Stay within the palpable fat deposit. Avoid injecting into the axillary lymph node cluster (palpate first — if lymph nodes are palpable, avoid that area). Stay superficial to the serratus anterior muscle laterally. |
|
Total volume per session |
2–8ml depending on deposit size. Larger deposits may require multiple sessions. |
|
Post-treatment |
Compression bra or garment for 2–4 weeks. Ice immediately post-treatment. |
|
Sessions typically required |
2–4 sessions spaced 6–8 weeks apart |
|
Axillary lymph node precaution: The axilla contains the axillary lymph node cluster — one of the most accessible lymphatic drainage points in the body. Palpate carefully before marking the injection zone. Any palpable, tender lymph node tissue should be excluded from the injection field. DCA injected into a lymph node causes painful, prolonged lymphadenopathy. Mark the boundaries conservatively and stay within the clearly palpable subcutaneous fat deposit. |
Zone 2: Localised Abdominal Fat
|
LOCALISED ABDOMINAL FAT — Clinical Overview |
|
Description: Injectable lipolytics for the abdomen address small, localised subcutaneous fat deposits — not generalised abdominal adiposity. The most appropriate abdominal candidates have a relatively lean body overall with a specific, pinchable subcutaneous fat deposit that persists despite exercise and diet. The critical distinction: subcutaneous vs visceral: Visceral fat (the fat around internal organs that contributes to the metabolically significant 'apple shape') is not accessible to injectable lipolytics. Only subcutaneous fat — above the rectus fascia, below the skin — is the treatment target. Patients with predominantly visceral abdominal fat will not respond. Assess by pinch test: if you can pinch a substantial fold of skin and subcutaneous fat above the rectus, there is subcutaneous fat to treat. Volume considerations: The abdomen has significantly more fat volume potential than the submental zone — larger deposits require more product per session and more sessions. For extensive deposits, surgical liposuction is more appropriate. Skin laxity risk: Significant in post-partum patients and in patients who have lost substantial weight. Assess skin laxity carefully — fat reduction without skin tightening may worsen abdominal appearance. Consider combining with RF tightening after fat reduction is complete. |
|
Parameter |
Abdominal Fat Protocol |
|
Patient position |
Supine, relaxed — patient not contracting the abdominals |
|
Injection depth target |
Subcutaneous fat — above the rectus fascia. In most patients this is 1.5–3cm below the skin surface. |
|
Safe zone boundaries |
Stay within the palpable subcutaneous fat deposit. Do not inject below the rectus fascia (risk of intramuscular injection). Avoid the umbilicus (periumbilical injection carries infection risk and irregular response). Avoid the linea alba midline scar if present. |
|
Needle gauge |
27G or 30G, 13mm length. Slightly larger gauge for the greater injection volume sometimes used here. |
|
Volume per point |
0.2–0.3ml per point depending on fat depth and product |
|
Point spacing |
1–1.5cm grid |
|
Total volume per zone per session |
5–15ml depending on deposit area and depth. Split across multiple treatment zones if treating both upper and lower abdomen. |
|
Post-treatment |
Compression garment for 2–4 weeks is strongly recommended to support the treated tissue during the inflammatory clearance phase. |
|
Sessions |
3–6 sessions typically required for meaningful abdominal contouring |
|
Post-partum abdominal precaution: Post-partum patients frequently present with a combination of diastasis recti (separation of the rectus muscles), excess subcutaneous fat, and significant skin laxity. Injectable lipolytics can address the subcutaneous fat component but will not improve the diastasis (a structural muscular issue requiring physiotherapy or surgery) or the skin laxity. Assess for diastasis recti before treating post-partum abdomens — injecting with diastasis recti present requires extra care to avoid placing product through the midline defect into the abdominal cavity. |
Zone 3: Inner Thigh Fat
|
INNER THIGH FAT — Clinical Overview |
|
Description: The medial thigh fat deposit — the tissue on the inner surface of the upper and mid-thigh — is a common localised fat concern, particularly in women. The fat deposit in this zone is often highly resistant to exercise and creates the thigh-rubbing concern that patients find uncomfortable in warm weather. Why this zone is treated differently: The inner thigh is affected by gravity-dependent oedema more than most zones — post-treatment swelling extends downward along the thigh from the injection site, creating visible, uncomfortable swelling that may affect walking for the first week. Patients must be specifically counselled about this. Skin quality: The inner thigh skin is generally thinner and less elastic than the bra-strap area. Assess for cellulite — lipolytic treatment does not improve cellulite texture (which involves fibrous septa in the fat, not pure adipocyte volume) and may make surface irregularity more apparent by reducing the fat volume beneath the fibrous bands. Bilateral treatment: Both thighs are typically treated in the same session — treating one side and not the other creates visible asymmetry during the interim period. |
|
Parameter |
Inner Thigh Protocol |
|
Patient position |
Standing for marking. Supine or side-lying for injection — depending on the specific subzone being treated. |
|
Safe zone boundaries |
Within the palpable subcutaneous fat deposit on the medial thigh surface. Avoid the great saphenous vein — it runs along the medial thigh and is often visible or palpable. Aspiration before each injection is particularly important in this zone. Avoid the groin crease — lymphatic channels run through the inguinal fold. |
|
Needle gauge |
30G or 31G, 13mm |
|
Volume per point |
0.2ml per point |
|
Point spacing |
1–1.5cm grid across the defined fat zone on the medial thigh surface |
|
Total volume per session |
4–12ml per side depending on deposit volume |
|
Compression |
Compression shorts or cycling shorts for 2–4 weeks post-treatment. Essential given gravity-dependent swelling in this zone. |
|
Sessions |
3–5 sessions typically required |
|
Specific patient advice |
Swelling may extend to the lower leg due to gravity. Warn patients about this before treatment. Swelling may affect comfort walking for 3–7 days. Plan treatment around social and work commitments. |
Zone 4: Medial Knee Fat
|
MEDIAL KNEE FAT — Clinical Overview |
|
Description: A small, discrete fat deposit medial to the knee — the fullness on the inner aspect of the knee that creates a rounded contour between the lower thigh and upper calf. This is one of the most diet-resistant fat deposits on the body and one where injectable lipolytic treatment often produces dramatic, highly appreciated results relative to the small treatment area and volume involved. Why patients value this: Many patients with this deposit have tried everything to address it and have assumed surgery is the only option. The knee fat pad is small, precisely targetable, and responds well to DCA — making it one of the more technically rewarding off-label applications. Safety profile: Favourable — the knee medial fat deposit is well-defined, subcutaneous, and not adjacent to major neurovascular structures in the way some body zones are. The medial knee is a technically accessible zone. |
|
Parameter |
Medial Knee Protocol |
|
Patient position |
Standing for marking. Supine or sitting for injection. |
|
Safe zone boundaries |
Within the palpable subcutaneous fat deposit medial to the knee. Do not inject into the knee joint space. Stay above the tibial plateau and below the medial femoral condyle — the joint line is the inferior boundary. Avoid the great saphenous vein (runs medially at the knee level). |
|
Needle gauge |
30G or 31G, 13mm |
|
Volume per point |
0.1–0.2ml — smaller volumes appropriate given the small fat volume in this zone |
|
Point spacing |
1cm grid |
|
Total volume per session |
2–4ml per knee — the deposit is small; excess product increases risk of reaching the knee joint space |
|
Bilateral treatment |
Treat both knees in the same session for symmetrical results |
|
Sessions |
1–3 sessions typically sufficient — the medial knee deposit is small and responds relatively quickly |
|
Post-treatment |
Compression bandage or knee-length compression sock for 1–2 weeks. |
Zone 5: Upper Arm Fat ('Bingo Wings')
|
UPPER ARM FAT — Clinical Overview |
|
Description: Posterior upper arm fat — the excess tissue on the back of the upper arm that creates the 'bingo wing' appearance when the arm is extended. This deposit is predominantly subcutaneous fat with, in some patients, a skin laxity component. Patient selection is critical: Carefully distinguish between fat (soft, compressible, positive pinch test) and skin laxity (the loose skin hangs regardless of pinching with minimal underlying compressible tissue). Fat responds to lipolytic treatment; skin laxity does not and may worsen. Many patients presenting with 'bingo wings' have predominantly skin laxity rather than fat — they are not lipolytic candidates. Anatomy consideration: The radial nerve and brachial vessels run through the upper arm but are deep to the triceps muscle — well protected from correctly placed superficial subcutaneous injection. The injection must remain superficial and subcutaneous to avoid any neurovascular risk. Skin laxity post-treatment: Reducing fat beneath already-lax upper arm skin consistently worsens the laxity appearance. Screen carefully with the pinch test. For patients with combined fat and laxity, lipolytic treatment combined with RF tightening (treated sequentially) produces the best outcomes. |
|
Parameter |
Upper Arm Protocol |
|
Patient position |
Arm extended at 90 degrees, supported, to stretch the posterior arm skin taut for marking and injection |
|
Safe zone boundaries |
Posterior upper arm — the fat depot on the back of the arm between the axilla and the elbow. Stay subcutaneous — well above the triceps muscle fascia. Do not inject into the axilla itself. |
|
Needle gauge |
30G, 13mm |
|
Volume per point |
0.2ml per point |
|
Point spacing |
1–1.5cm |
|
Total volume per session |
4–8ml per arm — treat both arms in the same session |
|
Compression |
Compression arm sleeves for 2–4 weeks post-treatment. Essential for managing gravity-dependent swelling. |
|
Sessions |
2–4 sessions |
|
Critical assessment |
Re-examine the pinch test result at the pre-treatment review. Confirm compressible fat is the primary concern, not skin laxity, before each session. |
Zone 6: Cervicodosal Fat Pad ('Buffalo Hump')
|
BUFFALO HUMP — Clinical Overview |
|
Description: A localised fat deposit at the base of the neck / upper back, creating a rounded protrusion at the cervicodosal junction (where the neck meets the upper back). Causes include idiopathic localised fat deposition, steroid-induced lipodystrophy (including long-term corticosteroid use), and HIV-associated lipodystrophy from antiretroviral therapy. Important: Confirm the cause before treating: Buffalo hump secondary to active steroid use or active HIV-associated lipodystrophy requires the underlying condition to be managed before lipolytic treatment. Treating a symptomatic secondary buffalo hump with lipolytics while the causative condition is ongoing will produce a temporary result at best. Anatomy: The deposit sits in the subcutaneous layer above the ligamentum nuchae and the cervical paraspinal musculature. The spinal cord, vertebral vessels, and deep cervical structures are well below the subcutaneous fat and are not at risk from correctly placed superficial injections. The deposit is generally well-defined and easily palpable. Clinical experience: Korean aesthetic practitioners have extensive experience treating this zone — particularly for idiopathic cervicodosal fat deposits — and results are consistently well-regarded when the deposit is of appropriate type and size. |
|
Parameter |
Buffalo Hump Protocol |
|
Patient position |
Prone or seated with neck flexed forward to present the fat pad for access |
|
Safe zone boundaries |
Within the palpable subcutaneous fat deposit at the cervicodosal junction. Stay superficial to the trapezius fascia. Do not inject medially into the posterior cervical midline. Stay within the clearly palpable fat pad. |
|
Needle gauge |
30G, 13mm |
|
Volume per point |
0.2ml per point |
|
Point spacing |
1cm grid across the fat pad |
|
Total volume per session |
4–10ml depending on deposit size |
|
Post-treatment |
Soft collar or neck support not generally needed. Ice and normal activity. Sleeping prone may be uncomfortable for the first few nights. |
|
Sessions |
2–4 sessions typically required |
|
Cause assessment |
Confirm idiopathic or resolved secondary cause before treating. |
Off-Label Zone Comparison: Quick Reference
|
Zone |
Evidence Level |
Typical Sessions |
Primary Risk |
Key Patient Caveat |
Compression Needed? |
|
Bra-strap / axillary fold |
Moderate |
2–4 |
Axillary lymph node injection — palpate and exclude first |
Significant swelling under the bra line for 2–3 weeks |
Yes — supportive bra |
|
Localised abdomen |
Moderate |
3–6 |
Intramuscular injection — stay above rectus fascia. Avoid umbilicus. |
More sessions needed than submental. Laxity assessment essential. |
Yes — compression garment |
|
Inner thighs |
Moderate |
3–5 |
Great saphenous vein proximity — aspirate every point. Gravity-dependent oedema. |
Swelling may extend to lower leg. May affect walking for 1 week. |
Yes — compression shorts |
|
Medial knee |
Moderate |
1–3 |
Knee joint proximity — stay above tibial plateau |
One of the most predictable off-label zones. Small volume = faster clearance. |
Yes — compression sock |
|
Upper arms |
Moderate |
2–4 |
Fat vs laxity distinction — laxity is not a lipolytic indication |
Rigorously assess for skin laxity. Removing fat under lax skin worsens appearance. |
Yes — compression sleeve |
|
Buffalo hump |
Moderate — Korean clinical experience |
2–4 |
Confirm cause (idiopathic vs active steroid/HIV) before treating |
Ongoing causative condition negates sustained result. |
No |
Universal Principles Across All Body Zones
Regardless of the specific treatment zone, the following principles apply universally to all off-label body lipolytic applications:
• Compression garments are not optional: With the exception of the buffalo hump, every body zone benefits significantly from post-treatment compression. Compression reduces the severity and duration of gravity-dependent swelling, supports the treated tissue during the inflammatory clearance phase, and may improve the evenness of the contour result. Advise patients to source appropriate garments before the treatment session.
• Swelling will be more pronounced in body zones than in the submental: The submental zone is small and well-supported by adjacent structures. Body zones — particularly the thighs and abdomen — have greater tissue volume and are more affected by gravitational swelling. The abdominal treated area at 72 hours post-treatment may look noticeably larger than before treatment. The inner thigh swelling may affect walking. Counsel patients explicitly about body-zone-specific swelling.
• Multiple sessions and longer total treatment timelines: Body fat deposits are generally larger than the submental deposit — requiring more sessions, more product per session, and longer total treatment timelines before the full result is achieved. Set cumulative treatment timelines at consultation: 'We are looking at 3–5 sessions, spaced 6–8 weeks apart — that's 5–8 months of treatment before we assess the final result.'
• The same absolute and relative contraindications apply: Active infection, pregnancy, anticoagulant therapy, significant skin laxity, and unrealistic expectations all apply as contraindications or precautions in body zones exactly as they do for submental treatment.
• Aspiration before every injection: In body zones with vascular proximity — particularly the inner thigh (great saphenous vein), the axillary fold (axillary vessels), and the abdomen (superficial epigastric vessels) — aspiration before every injection is a non-negotiable standard.
Korean Lipolytic Products for Body Applications
Korean CE-marked lipolytic formulations available through Celmade's lipolytic range are appropriate for both submental and off-label body applications. The same DCA and PC/DCA products used for submental treatment are used for body zones — with the same pharmaceutical-grade quality, full documentation, and MFDS + CE dual regulatory validation.
For body applications where larger volumes are required per session (abdomen, inner thighs, upper arms), the cost advantage of Korean products relative to European equivalents becomes particularly significant. A full inner thigh treatment course (3–5 sessions × 8–12ml per session) involves considerably more product volume than a submental course — and the 30–50% wholesale cost advantage of Korean CE-marked DCA over European alternatives makes comprehensive body treatment economically viable at patient-competitive pricing.
|
Product selection for body applications: The same product that works for submental fat works for all the body zones described in this guide. There is no need for a body-specific formulation — DCA at standard clinical concentrations (1–2%) or PC/DCA combination products are appropriate for all subcutaneous body fat applications. The volume per session differs; the product does not. Confirm product-specific guidance with Celmade for your intended applications. |
Key Takeaways
• Off-label body lipolytic applications are well-established in international practice — particularly in the Korean market — with extensive clinical experience supporting their safety and effectiveness when performed with appropriate patient selection and technique.
• Every zone has its own safety boundaries — axillary lymph nodes (bra zone), rectus fascia and umbilicus (abdomen), great saphenous vein and inguinal fold (inner thigh), knee joint line (medial knee), triceps fascia (upper arm), and deep cervical structures (buffalo hump).
• Skin laxity assessment is essential before treating the abdomen, thighs, and upper arms — fat reduction under lax skin worsens rather than improves the aesthetic outcome in these zones.
• Compression garments are required for all body zones except the buffalo hump — advise patients to have garments before treatment.
• Post-treatment swelling is more pronounced and longer-lasting in body zones — counsel every body patient on zone-specific swelling expectations before the first session.
• Korean CE-marked DCA from Celmade covers all applications — same product, full documentation, 30–50% lower wholesale cost. The cost advantage compounds significantly across larger body treatment volumes. Browse the lipolytic collection.
For related guides: Complete Lipolytic Injectables Guide, Submental Fat Reduction: Patient Selection and Protocol. Browse lipolytic products at Celmade.
Frequently Asked Questions
Which body zone produces the best results with injectable lipolytics?
The medial knee and bra-strap zones tend to produce the most consistently appreciated results relative to treatment volume and effort. Both zones have small, well-defined fat deposits that are highly resistant to diet and exercise — patients have typically tried everything else and find the injectable result life-changing in comparison to previous futility. The abdomen and inner thighs require more sessions and generate more swelling but can produce significant improvements in the right patients. All zones produce better results when patients are at healthy weight, have good skin elasticity, and have isolated fat deposits rather than generalised adiposity.
Is the swelling worse in body zones than the chin?
Yes — generally. The submental zone is small and the tissue is somewhat supported by the surrounding anatomy. Body zones — particularly the inner thighs, abdomen, and upper arms — are larger treatment areas with more tissue volume and are more affected by gravity-dependent swelling. Inner thigh swelling is the most notable: the inflammatory clearance fluids track downward along the thigh, creating visible swelling that may extend to the knee and lower leg and may affect walking comfort for the first 5–7 days. Compression garments significantly reduce this effect but do not eliminate it.
Can I treat multiple body zones in the same session?
Yes — treating multiple zones in the same session is common in experienced practices, provided the total product volume per session does not exceed safe limits and the patient can tolerate the cumulative inflammatory response. Typical same-session combinations: bra-strap + upper arms (patient is already prone), or inner thighs + medial knees (bilateral, similar position). Advise patients planning multi-zone treatment that post-treatment recovery will be more pronounced than single-zone treatment. A reasonable maximum is 2 zones per session for most patients.
How do I explain the off-label nature of body lipolytic treatment to patients?
"The product I'm using is CE-marked and made to pharmaceutical standards — it has an excellent safety record and has been used safely for these applications by practitioners internationally, including in Korea where this type of treatment has been performed for over 20 years. However, it was specifically licensed for use under the chin, so using it in other body areas is what's called 'off-label' use — which means using a licensed product for an indication not specifically listed on its licence. This is very common in medical practice and entirely legal, but I want to be transparent with you about it. The clinical results from these applications are well-documented, and I'm confident it's appropriate for your concern — but you should know this distinction when giving your consent."
What is the minimum sessions recommended for abdominal lipolytic treatment?
Meaningful abdominal contouring with injectable lipolytics typically requires 3–6 sessions spaced 6–8 weeks apart. This is a longer and more substantial commitment than submental treatment. Patients who are not prepared to commit to a full treatment course from the outset should have their expectations managed accordingly — 1–2 sessions alone are unlikely to produce visible abdominal contour change in patients with more than minimal fat volumes. Set the full treatment plan at consultation and confirm the patient's commitment before beginning.
